Breast cancer survivorship issues

Hematology/Oncology Clinics of North America

Volumn 27, Issue 4, 2013, Pages 805-827

  Stan, Daniela ^a   Loprinzi, Charles L ^a   Ruddy, Kathryn J ^b  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cognitive changes; Infertility; Musculoskeletal pain; Neuropathy; Osteoporosis; Sexual dysfunction; Treatment related cancers; Vasomotor symptoms

Indexed keywords

ALPHA TOCOPHEROL; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ASTROGLIDE; BRAIN NATRIURETIC PEPTIDE; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; CONJUGATED ESTROGEN; DESVENLAFAXINE; ENDOXIFEN; ESCITALOPRAM; ESTRADIOL; ESTROGEN; FLUOXETINE; GABAPENTIN; GINSENG EXTRACT; KY JELLY; LUBRICATING AGENT; MEGESTROL ACETATE; PAROXETINE; PHYTOESTROGEN; PLACEBO; POLYCARBOPHIL; PRASTERONE; PREGABALIN; PRIMROSE OIL; SERTRALINE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ACTAEA RACEMOSA; ACUPUNCTURE; AMENORRHEA; ANAMNESIS; ANOREXIA; ANXIETY DISORDER; BLOOD ANALYSIS; BONE SCINTISCANNING; BREAST CANCER; BREATHING; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVOR; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CREAM; DECREASED APPETITE; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVENING PRIMROSE; EXERCISE; FATIGUE; GINSENG; HOT FLUSH; HUMAN; HYPNOSIS; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LOW DRUG DOSE; MAMMOGRAPHY; MENSTRUATION; NAUSEA; PAIN; PARTIAL MASTECTOMY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYMPTOM; THORAX RADIOGRAPHY; VAGINAL DRYNESS; VAGINAL LUBRICATION; VASOMOTOR DISORDER; XEROSTOMIA; YAM; YOGA;

COGNITIVE CHANGES; INFERTILITY; MUSCULOSKELETAL PAIN; NEUROPATHY; OSTEOPOROSIS; SEXUAL DYSFUNCTION; TREATMENT-RELATED CANCERS; VASOMOTOR SYMPTOMS;

BREAST NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; QUALITY OF LIFE; SURVIVORS;

EID: 84881314905     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.05.005     Document Type: Review

References (150)

1. Pandya K.J., McFadden E.T., Kalish L.A., et al. Aretrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report. Cancer 1985, 55(1):202-205.
2. Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology. JClin Oncol 1997, 15(5):2149-2156.
3. Rosselli Del Turco M., Palli D., Cariddi A., et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994, 271(20):1593-1597.
4. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 1994, 271(20):1587-1592.
5. Khatcheressian J.L., Wolff A.C., Smith T.J., et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. JClin Oncol 2006, 24(31):5091-5097.
6. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75-89.
7. Gupta P., Sturdee D.W., Palin S.L., et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006, 9(1):49-58.
8. Loprinzi C.L., Zahasky K.M., Sloan J.A., et al. Tamoxifen-induced hot flashes. Clin Breast Cancer 2000, 1(1):52-56.
9. Cella D., Fallowfield L.J. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008, 107(2):167-180.
10. North American Menopause Society Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010, 17(2):242-255.
11. Bertelli G., Venturini M., Del Mastro L., et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002, 13(6):883-888.
12. Loprinzi C.L., Michalak J.C., Quella S.K., et al. Megestrol acetate for the prevention of hot flashes. NEngl J Med 1994, 331(6):347-352.
13. Bordeleau L., Pritchard K.I., Loprinzi C.L., et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. JClin Oncol 2010, 28(35):5147-5152.
14. Pandya K.J., Morrow G.R., Roscoe J.A., et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005, 366(9488):818-824.
15. Loprinzi C.L., Qin R., Balcueva E.P., et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. JClin Oncol 2010, 28(4):641-647.
16. Goldberg R.M., Loprinzi C.L., O'Fallon J.R., et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. JClin Oncol 1994, 12(1):155-158.
17. Sideras K., Ingle J.N., Ames M.M., et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. JClin Oncol 2010, 28(16):2768-2776.
18. Bordeleau L., Pritchard K., Goodwin P., et al. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther 2007, 29(2):230-241.
19. Ziaei S., Kazemnejad A., Zareai M. The effect of vitamin E on hot flashes in menopausal women. Gynecol Obstet Invest 2007, 64(4):204-207.
20. Tremblay A., Sheeran L., Aranda S.K. Psychoeducational interventions to alleviate hot flashes: a systematic review. Menopause 2008, 15(1):193-202.
21. Porzio G., Trapasso T., Martelli S., et al. Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifen. Tumori 2002, 88(2):128-130.
22. Vincent A., Barton D.L., Mandrekar J.N., et al. Acupuncture for hot flashes: a randomized, sham-controlled clinical study. Menopause 2007, 14(1):45-52.
23. Daley A.J., Stokes-Lampard H.J., Macarthur C. Exercise to reduce vasomotor and other menopausal symptoms: a review. Maturitas 2009, 63(3):176-180.
24. Elkins G.R., Fisher W.I., Johnson A.K., et al. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2012, [Epub ahead of print].
25. Elkins G., Marcus J., Stearns V., et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. JClin Oncol 2008, 26(31):5022-5026.
26. Bober S.L., Varela V.S. Sexuality in adult cancer survivors: challenges and intervention. JClin Oncol 2012, 30(30):3712-3719.
27. Thors C.L., Broeckel J.A., Jacobsen P.B. Sexual functioning in breast cancer survivors. Cancer Control 2001, 8(5):442-448.
28. Ganz P.A., Desmond K.A., Belin T.R., et al. Predictors of sexual health in women after a breast cancer diagnosis. JClin Oncol 1999, 17(8):2371-2380.
29. Joly F., Espie M., Marty M., et al. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer 2000, 83(5):577-582.
30. Ganz P.A., Rowland J.H., Desmond K., et al. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. JClin Oncol 1998, 16(2):501-514.
31. Fallowfield L., Cella D., Cuzick L., et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. JClin Oncol 2004, 22(21):4261-4271.
32. Jones S.E., Cantrell J., Vukelja S., et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a tamoxifen exemestane adjuvant multicenter trial substudy. JClin Oncol 2007, 25(30):4765-4771.
33. Katz A. The sounds of silence: sexuality information for cancer patients. JClin Oncol 2005, 23(1):238-241.
34. Reese J.B., Keefe F.J., Somers T.J., et al. Coping with sexual concerns after cancer: the use of flexible coping. Support Care Cancer 2010, 18(7):785-800.
35. Rosen R., Brown C., Heiman J., et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. JSex Marital Ther 2000, 26(2):191-208.
36. Ganz P.A., Greendale G.A., Petersen L., et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. JNatl Cancer Inst 2000, 92(13):1054-1064.
37. Loprinzi C.L., Abu-Ghazaleh S., Sloan J.A., et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. JClin Oncol 1997, 15(3):969-973.
38. Kendall A., Dowsett M., Folkerd E., et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006, 17(4):584-587.
39. Labrie F., Archer D., Bouchard C., et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009, 16(5):907-922.
40. Barton D.L., Wender D.B., Sloan J.A., et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. JNatl Cancer Inst 2007, 99(9):672-679.
41. Carter J., Goldfrank D., Schover L.R. Simple strategies for vaginal health promotion in cancer survivors. JSex Med 2011, 8(2):549-559.
42. Lustberg M.B., Reinbolt R.E., Shapiro C.L. Bone health in adult cancer survivorship. JClin Oncol 2012, 30(30):3665-3674.
43. Howard-Anderson J., Ganz P.A., Bower J.E., et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. JNatl Cancer Inst 2012, 104(5):386-405.
44. Partridge A.H., Gelber S., Peppercorn J., et al. Web-based survey of fertility issues in young women with breast cancer. JClin Oncol 2004, 22(20):4174-4183.
45. Oktay K., Hourvitz A., Sahin G., et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. JClin Endocrinol Metab 2006, 91(10):3885-3890.
46. Oktay K., Buyuk E., Libertella N., et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. JClin Oncol 2005, 23(19):4347-4353.
47. Azim A.A., Costantini-Ferrando M., Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. JClin Oncol 2008, 26(16):2630-2635.
48. Oktay K., Oktem O. Ovarian cryopreservation and transplantation for fertility preservation for medical indications: report of an ongoing experience. Fertil Steril 2010, 93(3):762-768.
49. Peate M., Meiser B., Cheah B.C., et al. Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. Br J Cancer 2012, 106(6):1053-1061.
50. Meneses K., McNees P., Azuero A., et al. Evaluation of the Fertility and Cancer Project (FCP) among young breast cancer survivors. Psychooncology 2010, 19(10):1112-1115.
51. Kanis J.A., McCloskey E.V., Powles T., et al. Ahigh incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79(7-8):1179-1181.
52. Powles T.J., Hickish T., Kanis J.A., et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. JClin Oncol 1996, 14(1):78-84.
53. Kristensen B., Ejlertsen B., Dalgaard P., et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. JClin Oncol 1994, 12(5):992-997.
54. Shapiro C.L., Manola J., Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. JClin Oncol 2001, 19(14):3306-3311.
55. Sverrisdottir A., Fornander T., Jacobsson H., et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. JClin Oncol 2004, 22(18):3694-3699.
56. Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. JClin Oncol 2008, 26(7):1051-1057.
57. Cuzick J., Sestak I., Baum M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11(12):1135-1141.
58. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8(2):119-127.
59. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. JClin Oncol 2006, 24(22):3629-3635.
60. Siris E.S., Brenneman S.K., Barrett-Connor E., et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 2006, 17(4):565-574.
61. Available at: Accessed February 21, 2013. http://www.shef.ac.uk/FRAX.
62. Hadji P., Aapro M.S., Body J.J., et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011, 22(12):2546-2555.
63. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. JClin Oncol 2003, 21(21):4042-4057.
64. Gralow J.R., Biermann J.S., Farooki A., et al. NCCN task force report: bone health in cancer care. JNatl Compr Canc Netw 2009, 7(Suppl 3):S1-S32. [quiz: S33-5].
65. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. JClin Oncol 2008, 26(30):4875-4882.
66. Hershman D.L., McMahon D.J., Crew K.D., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. JClin Oncol 2008, 26(29):4739-4745.
67. Mauri D., Valachis A., Polyzos N.P., et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. JNatl Compr Canc Netw 2010, 8(3):279-286.
68. Whitaker M., Guo J., Kehoe T., et al. Bisphosphonates for osteoporosis: where do we go from here?. NEngl J Med 2012, 366(22):2048-2051.
69. Baum M., Buzdar A., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98(9):1802-1810.
70. Crew K.D., Greenlee H., Capodice J., et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. JClin Oncol 2007, 25(25):3877-3883.
71. Morales L., Pans S., Verschueren K., et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. JClin Oncol 2008, 26(19):3147-3152.
72. Goodwin P.J., Ennis M., Pritchard K.I., et al. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. JClin Oncol 1999, 17(1):120-129.
73. Sestak I., Harvie M., Howell A., et al. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat 2012, 134(2):727-734.
74. Demark-Wahnefried W., Winer E.P., Rimer B.K. Why women gain weight with adjuvant chemotherapy for breast cancer. JClin Oncol 1993, 11(7):1418-1429.
75. Caan B.J., Emond J.A., Natarajan L., et al. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat 2006, 99(1):47-57.
76. Pierce J.P., Natarajan L., Caan B.J., et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007, 298(3):289-298.
77. Djuric Z., DiLaura N.M., Jenkins I., et al. Combining weight-loss counseling with the weight watchers plan for obese breast cancer survivors. Obes Res 2002, 10(7):657-665.
78. Schmitz K.H., Courneya K.S., Matthews C., et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010, 42(7):1409-1426.
79. Rock C.L., Doyle C., Demark-Wahnefried W., et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012, 62(4):243-274.
80. Ahles T.A., Root J.C., Ryan E.L. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. JClin Oncol 2012, 30(30):3675-3686.
81. Hermelink K., Untch M., Lux M.P., et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007, 109(9):1905-1913.
82. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7(3):192-201.
83. Schilder C.M., Seynaeve C., Beex L.V., et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. JClin Oncol 2010, 28(8):1294-1300.
84. Ahles T.A., Saykin A.J., McDonald B.C., et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. JClin Oncol 2010, 28(29):4434-4440.
85. Ahles T.A., Saykin A.J., Noll W.W., et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003, 12(6):612-619.
86. Kohli S., Fisher S.G., Tra Y., et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009, 115(12):2605-2616.
87. Ferguson R.J., McDonald B.C., Rocque M.A., et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 2012, 21(2):176-186.
88. Available at: Accessed February 21, 2013. http://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf.
89. Vogelzang N.J., Breitbart W., Cella D., et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997, 34(3 Suppl 2):4-12.
90. Collado-Hidalgo A., Bower J.E., Ganz P.A., et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006, 12(9):2759-2766.
91. Cella D., Davis K., Breitbart W., et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. JClin Oncol 2001, 19(14):3385-3391.
92. Bower J.E., Ganz P.A., Desmond K.A., et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 2006, 106(4):751-758.
93. Available at: Accessed February 21, 2013. http://www.uptodate.com/contents/cancer-related-fatigue-treatment.
94. Zee P.C., Ancoli-Israel S., Participants W. Does effective management of sleep disorders reduce cancer-related fatigue?. Drugs 2009, 69:29-41.
95. Cramp F., Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2012, (11). CD006145.
96. Barton D.L., Soori G.S., Bauer B.A., et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 2010, 18(2):179-187.
97. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. NEngl J Med 2008, 358(16):1663-1671.
98. Rugo H., Barry W., Moreno-Aspitia A., et al. Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). JClin Oncol 2012, 30(Suppl). [abstract CRA1002].
99. Peters C.M., Jimenez-Andrade J.M., Jonas B.M., et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 2007, 203(1):42-54.
100. Loprinzi C.L., Reeves B.N., Dakhil S.R., et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. JClin Oncol 2011, 29(11):1472-1478.
101. Rao R., Michalak J., Sloan J., et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007, 110(9):2110-2118.
102. Lavoie Smith E.M., Pang H., Cirrincione C., et al. Aphase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN). JClin Oncol 2012, 30(Suppl). [abstract CRA9013].
103. Smith T.J., Coyne P.J., Parker G.L., et al. Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare(R)) for chemotherapy-induced peripheral neuropathy. JPain Symptom Manage 2010, 40(6):883-891.
104. Barton D.L., Wos E.J., Qin R., et al. Adouble-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011, 19(6):833-841.
105. Storey D., Colvin L., Scott A., et al. Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: a phase I study. JClin Oncol 2010, 28(15 Suppl):9129.
106. Bird B.R., Swain S.M. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008, 14(1):14-24.
107. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. JAm Coll Cardiol 2010, 55(3):213-220.
108. Ryberg M., Nielsen D., Skovsgaard T., et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. JClin Oncol 1998, 16(11):3502-3508.
109. Trudeau M., Charbonneau F., Gelmon K., et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 2005, 6(11):886-898.
110. Perez E.A., Suman V.J., Davidson N.E., et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. JClin Oncol 2004, 22(18):3700-3704.
111. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. NEngl J Med 2000, 342(15):1077-1084.
112. Torti F.M., Bristow M.R., Howes A.E., et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983, 99(6):745-749.
113. Benjamin R.C., Chawla S.P., Hortobagyi G. Clinical applications of continuous infusion chemotherapy and concomitant radiation therapy. Clinical applications of continuous infusion chemotherapy and concomitant radiation therapy 1986, 19-25. Plenum Press, New York. C. Rosenthal, M. Rotman (Eds.).
114. Ewer M.S., Von Hoff D.D., Benjamin R.S. Ahistorical perspective of anthracycline cardiotoxicity. Heart Fail Clin 2011, 7(3):363-372.
115. Marty M., Espie M., Llombart A., et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 2006, 17(4):614-622.
116. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEngl J Med 2005, 353(16):1659-1672.
117. Slamon D., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC -> TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. Cancer Res 2009, 69(24):500s.
118. Maitland M.L., Bakris G.L., Black H.R., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. JNatl Cancer Inst 2010, 102(9):596-604.
119. Bouillon K., Haddy N., Delaloge S., et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. JAm Coll Cardiol 2011, 57(4):445-452.
120. Taylor C.W., Povall J.M., McGale P., et al. Cardiac dose from tangential breast cancer radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys 2008, 72(2):501-507.
121. Amir E., Seruga B., Niraula S., et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. JNatl Cancer Inst 2011, 103(17):1299-1309.
122. Lenihan D.J., Cardinale D.M. Late cardiac effects of cancer treatment. JClin Oncol 2012, 30(30):3657-3664.
123. Cardinale D., Sandri M.T. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010, 53(2):121-129.
124. Howard R.A., Gilbert E.S., Chen B.E., et al. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat 2007, 105(3):359-368.
125. Arslan C., Ozdemir E., Dogan E., et al. Secondary hematological malignancies after treatment of non-metastatic breast cancer. JBUON 2011, 16(4):744-750.
126. Patt D.A., Duan Z., Fang S., et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. JClin Oncol 2007, 25(25):3871-3876.
127. Wood M.E., Vogel V., Ng A., et al. Second malignant neoplasms: assessment and strategies for risk reduction. JClin Oncol 2012, 30(30):3734-3745.
128. Kirova Y.M., De Rycke Y., Gambotti L., et al. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 2008, 98(5):870-874.
129. Andersson M., Jensen M.B., Engholm G., et al. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer Cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. Acta Oncol 2008, 47(4):755-764.
130. Martin M.G., Welch J.S., Luo J., et al. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat 2009, 118(3):593-598.
131. Hershman D., Neugut A.I., Jacobson J.S., et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. JNatl Cancer Inst 2007, 99(3):196-205.
132. Available at: 2012. Accessed February 21, 2013. http://www.nccn.org.
133. Hewitt M.G., Greenfield S., Stovall E. Committee on cancer survivorship: improving care and quality of life National Cancer Policy Board. From cancer patient to cancer survivor: lost in transition 2005, 187-321. Delivering cancer survivorship care, The National Academies Press, Washington, DC. Institute of Medicine and National Research Council of the National Academies (Ed.).
134. Grunfeld E., Julian J.A., Pond G., et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. JClin Oncol 2011, 29(36):4755-4762.
135. Earle C.C., Ganz P.A. Cancer survivorship care: don't let the perfect be the enemy of the good. JClin Oncol 2012, 30(30):3764-3768.
136. Loprinzi C.L., Barton D.L., Sloan J.A., et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause 2008, 15(4 Pt 1):655-660.
137. Loprinzi C.L., Sloan J., Stearns V., et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. JClin Oncol 2009, 27(17):2831-2837.
138. Loprinzi C.L., Levitt R., Barton D., et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. JClin Oncol 2006, 24(9):1409-1414.
139. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000, 356(9247):2059-2063.
140. Loprinzi C.L., Sloan J.A., Perez E.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. JClin Oncol 2002, 20(6):1578-1583.
141. Stearns V., Beebe K.L., Iyengar M., et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003, 289(21):2827-2834.
142. Stearns V., Slack R., Greep N., et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. JClin Oncol 2005, 23(28):6919-6930.
143. Kimmick G.G., Lovato J., McQuellon R., et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006, 12(2):114-122.
144. Gordon P.R., Kerwin J.P., Boesen K.G., et al. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 2006, 13(4):568-575.
145. Grady D., Cohen B., Tice J., et al. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007, 109(4):823-830.
146. Guttuso T., Kurlan R., McDermott M.P., et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003, 101(2):337-345.
147. Reddy S.Y., Warner H., Guttuso T., et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006, 108(1):41-48.
148. Barton D.L., Loprinzi C.L., Quella S.K., et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. JClin Oncol 1998, 16(2):495-500.
149. Quella S.K., Loprinzi C.L., Barton D.L., et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. JClin Oncol 2000, 18(5):1068-1074.
150. Pockaj B.A., Gallagher J.G., Loprinzi C.L., et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. JClin Oncol 2006, 24(18):2836-2841.